Olaparib Investigated After First-Line Chemo in Ovarian Cancer


Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.

The phase 3 MONO-OLA1 trial (NCT04884360) will investigate the use of olaparib (Lynparza) as maintenance therapy after response from platinum-based chemotherapy, for patients with BRCA1/2 wild-type advanced ovarian cancer, according to a poster presentation from The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.1

MONO-OLA1 will access the efficacy and safety of olaparib compared with placebo in patients with newly diagnosed BRCA1/2 wild-type advanced ovarian cancer after a complete response (CR) or partial response (PR) to frontline platinum-based chemotherapy.

Notably, BRCA wild-type disease presents in approximately 60% to 80% of patients with high-grade serous ovarian cancer, and viable treatment options for this patient population remain an unmet need.2 Maintenance therapy with a PARP inhibitor, with or without bevacizumab (Avastin), has demonstrated prior benefit non–BRCA-mutated advanced ovarian cancer.

MONO-OLA1 has a target enrollment of 420 women, who will be randomized 2:1 to receive 300 mg of olaparib tablets twice daily or placebo. Stratification factors will include response to first-line, platinum-based chemotherapy by CR or PR, homologous recombination deficiency (HRD) status, and region (China or other international sites). Notably, patients with HRD-negative or unknown status will be limited to approximately 60% of enrollment to ensure sufficient powering of the primary end point and reflect the real-world prevalence of BRCA wild-type, HRD-positive disease.

The primary end points of MONO-OLA1 are investigator-assessed PFS per RECIST v1.1 for patients with BRCA wild-type, HRD-positive disease, and investigator-assessed PFS per RECIST v1.1 for patients BRCA wild-type disease. Secondary end points include: overall survival; second PFS; time to first subsequent therapy or death; time to second subsequent therapy or death; time to earliest progression per RECIST v1.1, or CA-125, or death; quality of life using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire and its ovarian-specific module, EORTC QLQ-OV28; and safety. These end points are to be assessed in both BRCA wild-type, HRD-positive and BRCA wild-type patients.

Evaluation of safety and tolerability will include physical examination, laboratory testing, and adverse event reporting, graded according to Common Terminology Criteria for Adverse Events v5.0.

Translational analyses to identify predictive biomarkers of response and resistance to olaparib will be included as an exploratory end point.

Eligible patients must be at least 18 years old with histologically confirmed stage III or IV newly diagnosed high-grade serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. For patients with stage III disease, surgical criteria will include

primary debulking surgery with macroscopic residual disease following surgery, neoadjuvant chemotherapy, or inoperable disease. For those with stage IV disease, the surgical criteria are primary debulking surgery regardless of residual disease, neoadjuvant chemotherapy, or inoperable disease.

Additionally, patients will be required to have confirmed BRCA wild-type status per centrally performed tumor BRCA testing; clinical CR or PR per RECIST v1.1 criteria following first-line, platinum-based chemotherapy; no prior bevacizumab in combination with chemotherapy or planned bevacizumab maintenance therapy; and a minimum life expectancy of 16 weeks.

Patients will prior exposure to PARP inhibitors, including olaparib, or complete cytoreduction following primary debulking surgery with stage III disease, will be excluded from the trial.

The MONO-OLA1 is currently recruiting patients; the estimated primary completion date of July 2, 2024.3

Previously, results of a primary analysis from the phase 3 SOLO-1 trial (NCT01844986) showed that maintenance olaparib for patients with BRCA-mutant ovarian cancer generated a median progression-free survival (PFS) that was not reached compared with 13.8 months with placebo (HR, 0.30; 95% CI, 0.23-0.41; < .001).4 Results from SOLO-1 led to the FDA approval of maintenance olaparib in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer.


1. Saevets V, Yin R, Zhu J, Chen C, Ah-See ML, Wu X. MONO-OLA1: a randomized, Phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy. Poster presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022; Phoenix, Arizona. Accessed March 18, 2022. Abstract 334.

2. Choi MC, Bae JS, Jung SG, et al. Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube. J Gynecol Oncol. 2018;29(4):e43. doi:10.3802/jgo.2018.29.e43

3. D9319C00001- 1L OC Mono Global RCT (MONO-OLA1). ClinicalTrials.gov. Updated February 17, 2022. Accessed March 18, 2022. https://clinicaltrials.gov/ct2/show/NCT04884360

4. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Eng J Med. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content